|
AU675204B2
(en)
*
|
1992-06-25 |
1997-01-30 |
City Of Hope |
Induction of cytolytic T-lymphocytes with cytomegalovirus polypeptides
|
|
US20020151690A1
(en)
|
1997-08-12 |
2002-10-17 |
Luxemburg Alain T |
Purification of antigen-specific t cells
|
|
GB0029360D0
(en)
|
2000-12-01 |
2001-01-17 |
Univ Nottingham |
Humanised antibodies and uses thereof
|
|
JP4733635B2
(ja)
|
2003-07-31 |
2011-07-27 |
イミューノメディクス、インコーポレイテッド |
抗cd19抗体
|
|
US7855279B2
(en)
|
2005-09-27 |
2010-12-21 |
Amunix Operating, Inc. |
Unstructured recombinant polymers and uses thereof
|
|
CA2644712C
(en)
|
2006-03-06 |
2016-09-13 |
Amunix, Inc. |
Unstructured recombinant polymers and uses thereof
|
|
CA2695374A1
(en)
|
2007-08-15 |
2009-02-19 |
Amunix, Inc. |
Compositions and methods for modifying properties of biologically active polypeptides
|
|
HRP20150074T1
(hr)
|
2007-10-01 |
2015-03-13 |
Bristol-Myers Squibb Company |
Humana antitijela koja se vežu za mezotelin i njihove uporabe
|
|
KR101559599B1
(ko)
|
2007-11-26 |
2015-10-12 |
바이엘 인텔렉쳐 프로퍼티 게엠베하 |
항-메소텔린 항체 및 이의 용도
|
|
WO2009091826A2
(en)
|
2008-01-14 |
2009-07-23 |
The Board Of Regents Of The University Of Texas System |
Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car)
|
|
JP2012504961A
(ja)
|
2008-10-06 |
2012-03-01 |
ミネルバ バイオテクノロジーズ コーポレーション |
Muc1*抗体
|
|
MX356367B
(es)
|
2008-12-09 |
2018-05-25 |
Genentech Inc |
Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
|
|
DK3178835T3
(da)
|
2009-02-03 |
2019-06-24 |
Amunix Pharmaceuticals Inc |
Forlængede rekombinante polypeptider og sammensætninger omfattende samme
|
|
CA2756393C
(en)
|
2009-03-24 |
2017-06-20 |
The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services |
Anti-mesothelin antibodies
|
|
EP3279215B1
(en)
|
2009-11-24 |
2020-02-12 |
MedImmune Limited |
Targeted binding agents against b7-h1
|
|
PH12013501201A1
(en)
|
2010-12-09 |
2013-07-29 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
|
SG194567A1
(en)
|
2011-04-21 |
2013-12-30 |
Seattle Genetics Inc |
Novel binder-drug conjugates (adcs) and their use
|
|
WO2014031476A1
(en)
|
2012-08-21 |
2014-02-27 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Mesothelin domain-specific monoclonal antibodies and use thereof
|
|
US10117896B2
(en)
|
2012-10-05 |
2018-11-06 |
The Trustees Of The University Of Pennsylvania |
Use of a trans-signaling approach in chimeric antigen receptors
|
|
TW201425336A
(zh)
|
2012-12-07 |
2014-07-01 |
Amgen Inc |
Bcma抗原結合蛋白質
|
|
IL305629A
(en)
|
2013-02-15 |
2023-11-01 |
Univ California |
Chimeric antigen receptor and methods of using it
|
|
WO2015090229A1
(en)
|
2013-12-20 |
2015-06-25 |
Novartis Ag |
Regulatable chimeric antigen receptor
|
|
CN122399016A
(zh)
|
2014-03-15 |
2026-07-17 |
诺华股份有限公司 |
使用嵌合抗原受体治疗癌症
|
|
GB201406767D0
(en)
|
2014-04-15 |
2014-05-28 |
Cancer Rec Tech Ltd |
Humanized anti-Tn-MUC1 antibodies anf their conjugates
|
|
JP6652932B2
(ja)
*
|
2014-06-18 |
2020-02-26 |
アルバート アインシュタイン カレッジ オブ メディシン |
synTacポリペプチド及びその使用
|
|
AU2015292744C1
(en)
|
2014-07-21 |
2021-01-21 |
Novartis Ag |
Treatment of cancer using humanized anti-BCMA chimeric antigen receptor
|
|
UY36401A
(es)
|
2014-11-14 |
2016-06-30 |
Novartis Ag |
Conjugados anticuerpos-fármacos
|
|
EP3256494A4
(en)
|
2015-02-10 |
2018-12-05 |
Minerva Biotechnologies Corporation |
Humanized anti-muc1* antibodies
|
|
KR102618312B1
(ko)
|
2015-03-17 |
2023-12-28 |
메모리얼 슬로안 케터링 캔서 센터 |
항muc16 항체 및 그의 용도
|
|
MX383464B
(es)
|
2015-07-13 |
2025-03-14 |
Cytomx Therapeutics Inc |
Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos.
|
|
ES2913208T3
(es)
|
2015-12-01 |
2022-06-01 |
Glaxosmithkline Ip Dev Ltd |
Tratamientos de combinación y usos y métodos de los mismos
|
|
PT3393504T
(pt)
|
2015-12-22 |
2025-12-30 |
Novartis Ag |
Recetor de antigénio quimérico (car) de mesotelina e anticorpo contra o inibidor de pd-l1 para utilização combinada em terapia anticancerígena
|
|
CN113082201B
(zh)
*
|
2016-04-01 |
2024-07-05 |
上海斯丹赛生物技术有限公司 |
刺激t细胞介导的对表达抗原的细胞群的免疫应答的方法
|
|
JP7002769B2
(ja)
|
2016-09-16 |
2022-02-04 |
ベイラー カレッジ オブ メディスン |
ウイルス特異的t細胞の活性化および拡大のためのプラットフォーム
|
|
KR102531251B1
(ko)
|
2016-09-23 |
2023-05-15 |
리제너론 파아마슈티컬스, 인크. |
이특이적 항-muc16-cd3 항체 및 항-muc16 약물 접합체
|
|
DE102016225436A1
(de)
*
|
2016-12-19 |
2018-06-21 |
Volkswagen Aktiengesellschaft |
Sensor zum Erfassen von Messwerten, Verfahren, Vorrichtung und computerlesbares Speichermedium mit Instruktionen zur Verarbeitung von Messwerten eines Sensors
|
|
CN110325205B
(zh)
|
2016-12-22 |
2023-08-15 |
库尔生物制药有限公司 |
T细胞调节性多聚体多肽及其使用方法
|
|
WO2018129270A1
(en)
*
|
2017-01-05 |
2018-07-12 |
Fred Hutchinson Cancer Research Center |
Systems and methods to improve vaccine efficacy
|
|
EP3755711A4
(en)
*
|
2018-02-20 |
2021-11-24 |
Technion Research & Development Foundation Limited |
IMMUNOTHERAPEUTIC COMPOSITION FOR THE TREATMENT OF CANCER
|
|
KR20220015382A
(ko)
|
2019-05-29 |
2022-02-08 |
큐 바이오파마, 인크. |
다량체 t-세포 조절 폴리펩타이드 및 이의 사용 방법
|